7 news items
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
BLRX
30 May 24
in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
BLRX
28 May 24
, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
BLRX
24 May 24
in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
BLRX
22 May 24
in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
BLRX
17 May 24
in Israel, and with operations in the U.S., the company is driving innovative therapeutics
6enjyq6y yid0kpcaqdhfr5r1ki0erfx4rzx0j9131cnpocw3j
BLRX
6 May 24
in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development
nzc18vvlmcuu1q2irabpzvoiwbf71q5
BLRX
17 Apr 24
innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench
- Prev
- 1
- Next